Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran

Pierre Sié Hematology Laboratory, Academic Hospital of Toulouse, Hospital Rangueil, Toulouse, France Abstract: Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous thromboembolism and prevention of stroke in a...

Full description

Bibliographic Details
Published in:	Drug Design, Development and Therapy
Main Author:	Sié P
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-05-01
Subjects:	dabigatran idarucizumab bleeding surgery
Online Access:	https://www.dovepress.com/spotlight-on-idarucizumab-and-its-potential-for-the-reversal-of-antico-peer-reviewed-article-DDDT

Similar Items

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran
by: Jong-Min Kim, et al.
Published: (2025-07-01)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
by: Jameel Abdulrehman, et al.
Published: (2021-07-01)

The new way of Dabigatran reversal – Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019-02-01)

Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study)
by: Esme Ekizoğlu
Published: (2018-06-01)

IDARUCIZUMAB, A SPECIFIC REVERSAL AGENT FOR DABIGATRAN: THE PRESENT-DAY KNOWLEDGE
by: Olga O. Shakhmatova
Published: (2018-12-01)

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
by: Masahiro Yasaka, et al.
Published: (2020-03-01)

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
by: António Tralhão, et al.
Published: (2017-09-01)

Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
by: Jhih-Wei Dai, et al.
Published: (2023-05-01)

Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study
by: Masahiro Yasaka, et al.
Published: (2023-10-01)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
by: Hu TY, et al.
Published: (2016-02-01)

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
by: Valentin Held, et al.
Published: (2016-10-01)

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
by: Gail Edwards, et al.
Published: (2018-02-01)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
by: Maren Hieber, et al.
Published: (2019-03-01)

Idarucizumab (Praxbind®) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients
by: Eran Kalmanovich, et al.
Published: (2021-04-01)

Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report
by: Dan Xie, et al.
Published: (2021-12-01)

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
by: Sergio Agosti, et al.
Published: (2017-08-01)

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy
by: Ilga Kikule, et al.
Published: (2022-09-01)

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports
by: Tomić Milan
Published: (2020-01-01)

Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study
by: Nils Kuklik, et al.
Published: (2023-07-01)

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
by: Gorana Vukorepa, et al.
Published: (2020-01-01)

DABIGATRAN AND IDARUZIZUMAB. NEW OPPORTUNITIES FOR IMPROVING PATIENT SAFETY
by: N. A. Novikova, et al.
Published: (2019-06-01)

Idarucizumab Reversal in Subdural Hemorrhage: A Single-Center Experience
by: Anita Mrvar Brečko, et al.
Published: (2025-10-01)

Reversal of dabigatran and apixaban-induced coagulopathy using idarucizumab, fibrinogen, and prothrombin complex concentrate: A case report
by: Elia Morando, et al.
Published: (2024-11-01)

The first experience with thrombolytic therapy for cerebral infarction in the Russian Federation after the use of idarucizumab
by: E. V. Pudov, et al.
Published: (2020-02-01)

Practical use of idarucizumab
by: G. R. Ramazanov, et al.
Published: (2023-11-01)

Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab
by: Eiichi Suehiro, et al.
Published: (2023-11-01)

Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications
by: Maurizio Tala, et al.
Published: (2018-09-01)

Anticoagulant-related bleeding in patients with heart failure in combination with chronic obstructive pulmonary disease and atrial fibrillation. Experience with Idarucizumab
by: L. A. Shpagina, et al.
Published: (2020-06-01)

Idarucizumab in dabigatran-treated patients with acute stroke: a review and clinical update
by: Senta Frol, et al.
Published: (2024-05-01)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
by: Jong-Min Kim, et al.
Published: (2022-01-01)

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
by: E. I. Baranova
Published: (2018-11-01)

SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS
by: O. O. Shakhmatova
Published: (2016-07-01)

Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
by: Stephanie A. Kustos, et al.
Published: (2019-10-01)

Idarucizumab in High-risk Thoracic Surgery
by: R L�pez Vilella, et al.
Published: (2018-04-01)

Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate
by: Roisin Bavalia, et al.
Published: (2020-05-01)

Aspects of anticoagulant therapy in patients with atrial fibrillation in the light of updated guidelines of the European society of cardiology 2020: the position of dabigatran
by: E. S. Kropacheva, et al.
Published: (2020-12-01)

Systemic Thrombolytic Therapy for Ischemic Stroke in the Course of Anticoagulants
by: L. Kh.-B. Akhmatkhanova, et al.
Published: (2021-11-01)

The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis
by: S. P. Abdullaev, et al.
Published: (2020-11-01)

Dabigatran and Dental Procedures in Patients with High Risk Bleeding
by: Hossien Akbari, et al.
Published: (2024-01-01)